RenovoRx (RNXT) Cash & Equivalents (2020 - 2026)

RenovoRx has reported Cash & Equivalents for 7 years, with the latest figure at $12.4 million in Q1 2026.

• Quarterly Cash & Equivalents fell 15.22% year-over-year to $12.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.4 million (down 15.22% YoY) and the FY2025 annual result came in at $7.0 million, down 1.82% from the prior year.
• Cash & Equivalents improved to $12.4 million in Q1 2026 per RNXT's latest filing, from $7.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $14.6 million in Q1 2025 and troughed at $1.2 million in Q4 2023.
• A 5-year average of $7.4 million and a median of $7.0 million in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents slumped 82.53% in 2022, then soared 509.89% in 2024.
• Over 5 years, Cash & Equivalents stood at $4.4 million in 2022, then plunged by 73.29% to $1.2 million in 2023, then jumped by 509.89% to $7.2 million in 2024, then fell by 1.82% to $7.0 million in 2025, then soared by 76.0% to $12.4 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $12.4 million, $7.0 million, and $10.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.